{
    "id": 60074,
    "name": "ductal carcinoma in situ",
    "source": "DOID",
    "definition": "A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has_material_basis_in abnormally proliferating cells, derives_from epithelial cells. [url:https\\://www.breastcancer.org/symptoms/types/dcis, url:https\\://www.cancer.gov/publications/dictionaries/cancer-terms/search?contains=false&q=ductal+carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060074",
    "evidence": [
        {
            "id": 10237,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 5222,
                "therapyName": "HER2-pulsed DC1 vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 60074,
                "name": "ductal carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8179,
                    "pubMedId": 27965306,
                    "title": "Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27965306"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12936,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nolvadex (tamoxifen) therapy is included in guidelines for patients with ESR1-positive ductal carcinoma in situ (PMID: 31236598; ESMO.org, NCCN.org).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60074,
                "name": "ductal carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                },
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02636582",
            "title": "Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 5152,
                    "therapyName": "Nelipepimut-S Plus GM-CSF",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02694809",
            "title": "Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5928,
                    "therapyName": "Conjugated estrogens/bazedoxifene",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02872025",
            "title": "Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928978",
            "title": "Ruxolitinib for Premalignant Breast Disease",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02993159",
            "title": "Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5132,
                    "therapyName": "Afimoxifene",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03535506",
            "title": "Preoperative Palbociclib in Patients Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery (WI223281)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        }
    ]
}